October 11, 2024

To The Manager Listing Department **National Stock Exchange of India Limited** 'Exchange Plaza', C - 1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai 400051. Scrip Code: INDOCO	To **BSE Limited** Corporate Relationship Department 1st Floor, New Trading Ring, Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400001 Scrip Code : 532612

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 ('Listing Regulations').

We hereby inform and enclose a Press release regarding receipt of regulatory status from U.S. Food and Drug Administration (USFDA), for our facilities located at Goa Plant-II & III, L-32,33,34, Verna Industrial Area, Verna, Goa, Goa 403722, India (Facility), following an inspection conducted by USFDA in July 2024. USFDA has determined that the inspection classification of this Facility remains as "official action indicated" (OAI).

The Facility had been inspected by the USFDA in February 2023 and had received an OAI status in May 2023. Indoco is comprehensively working on the remedial action plan at the Facility which will be completed by Q3 2024.

Indoco had planned to inform USFDA for the inspection readiness post completion of the remedial action. However, USFDA visited the Facility in July 2024, while the remedial action was still in progress. Hence, the compliance status of the Facility received as 'OAI' dated 10th October 2024, remains the same.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

RAMANATHAN HARIHARAN
Digitally signed by RAMANATHAN HARIHARAN
Date: 2024.10.11 16:59:48 +05'30'

Ramanathan Hariharan
Company Secretary & Head Legal

PRESS RELEASE

Mumbai, October 11, 2024: Indoco Remedies Limited (Indoco) hereby informs receipt of regulatory status from U.S. Food and Drug Administration (USFDA), for our facilities located at Goa Plant-II & III, L-32,33,34, Verna Industrial Area, Verna, Goa, Goa 403722, India (Facility), following an inspection conducted by USFDA in July 2024. The USFDA has determined that the inspection classification of this Facility remains as 'Official Action Indicated' (OAI).

The Facility had been inspected by the USFDA in February 2023 and had received an OAI status in May 2023. Indoco is comprehensively working on the remedial action plan at the Facility which will be completed by Q3 2024.

Indoco had planned to inform USFDA for the inspection readiness post completion of the remedial action. However, USFDA had visited the Facility in July 2024, while the remedial action was still in progress. Hence, the compliance status of the Facility received as 'OAI' dated 10th October 2024, remains the same.

Commenting on this, **Ms. Aditi Panandikar, Managing Director** mentioned, "We are working holistically towards meeting the expectations of the regulators and are committed to remain focussed on compliance to deliver products of high-quality standards."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization. The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe. For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:
Corporate Communications | Mobile: +91 22 62871000 E-mail: corpcom@indoco.com